Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25053677 | 0.96 | NR5A1 (0.47) | CA12CA1CA2TSHRCA7 | |
| SCHEMBL25888663 | 0.93 | CA12 (0.47) | CA12CA1CA2TSHRCA7 | |
| SCHEMBL20249214 | 0.86 | CYP3A4 (0.39) | CYP3A4SMN1; SMN2 | |
| SCHEMBL12710188 | 0.85 | NQO1 (0.50) | CA12CA1CA2TSHRCA7 | |
| SCHEMBL20325139 | 0.84 | CA12 (0.43) | CA12CA1CA2TSHRCA7 | |
| SCHEMBL14093020 | 0.84 | NCF1 (0.43) | KDM4E | |
| SCHEMBL20249203 | 0.84 | CYP3A4 (0.47) | CYP2D6CYP2C9CYP2C19CYP19A1CYP3A4 | |
| SCHEMBL22043410 | 0.84 | CBFB (0.40) | KDM4E | |
| SCHEMBL20249212 | 0.83 | KDM4E (0.53) | CYP2D6CYP2C9CYP2C19CYP3A4SMN1; SMN2 | |
| SCHEMBL20234786 | 0.83 | HTR1B (0.50) | KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-11584743-B2 | Indole derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-3971176-A1 | AROMATIC AMINE AR AND BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE | Hinova Pharmaceuticals Inc. (CN) | 2022-03-23 | — | — | EP | disclosed |
| US-20190233433-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2019-08-01 | — | — | US | disclosed |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | CA12 4577/4885CA1 4753/4885CA2 2465/4885 |
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | CA12 3668/4885CA1 3341/4885CA2 4045/4885 |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | CA12 2628/4885CA1 982/4885CA2 3502/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | CA12 4488/4885CA1 2572/4885CA2 4367/4885 |
| US-11584743-B2 | Indole derivatives as estrogen receptor degraders | ESR1, GPER1, ESR2 | CA12 1766/4885CA1 1679/4885CA2 562/4885 |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | EGFR, ERBB2, ERBB3 | CA12 3208/4885CA1 3346/4885CA2 4124/4885 |
| US-20190233433-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | CA12 2354/4885CA1 539/4885CA2 2225/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | CA12 3204/4885CA1 1625/4885CA2 3308/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | CA12 3916/4885CA1 2650/4885CA2 4176/4885 |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | CA12 3916/4885CA1 2650/4885CA2 4176/4885 |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | CA12 2628/4885CA1 982/4885CA2 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.